Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Shahanawaz Jiwani, Min Fang, Cecilia Yeung, Xiaoyu QU, Xueyan Chen, Brent Wood, Andrea Zak, Srikrishna Narava, Ting-Chia Chang, Celso Baldivieso, Megha Kamath, Megan Othus, Bhanumati Ramineni, Harry Erba, Mark Litzow, James Doroshow, Lyndsay Harris, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 340.

https://doi.org/10.1182/blood-2025-340

Published: 2025

Journal Articles

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Xiaoyu QU, Kate Kroeger, Jacob Wilson, Alyssa Ng, Cecilia Yeung, Shahanawaz Jiwani, Lyndsay Harris, Brent Wood, Harry Erba, Jerald Radich, Richard Little

Blood (2025) 146 (Supplement 1): 3501.

https://doi.org/10.1182/blood-2025-3501

Published: 2025

Journal Articles

Impact of social determinants of health on access to molecular targeted therapy in AML and MDS: A real-world analysis

Pierantonio Russo, Ramaa Nathan, Daniel Pfeffer, Alison Roos, Cecilia Yeung

Blood (2025) 146 (Supplement 1): 3379.

https://doi.org/10.1182/blood-2025-3379

Published: 2025

Journal Articles

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Anjali Advani, Anna Moseley, Kristen O'Dwyer, Cecilia Yeung, Olga Sala Torra, Brent Wood, Jae Park, Matthew Wieduwilt, Deepa Jeyakumar, George Yaghmour, Ehab Atallah, Aaron Gerds, Susan O'Brien, Jane Liesveld, Megan Othus, Mark Litzow, Richard Stone, Jerald Radich, Harry Erba

Blood (2025) 146 (Supplement 1): 3343.

https://doi.org/10.1182/blood-2025-3343

Published: 2025

Journal Articles

Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries

Vivian Oehler, Olga Sala-Torra, Neta Gilderman, Lan Beppu, David Woolston, Priscilla Namaganda, Jennifer Rynning, Ines Garcia Gonzalez, Andrea Towlerton, Jenna Voutsinas, Qian Wu, Cecilia Yeung, Jerald Radich

Blood (2025) 146 (Supplement 1): 5559.

https://doi.org/10.1182/blood-2025-5559

Published: 2025

Journal Articles

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Kai Yu, Laura Dillon, Jesse Tettero, Gege Gui, Rasha Al-Ali, Michael Grunwald, Elizabeth Krakow, Elizabeth Griffiths, Alexandra Gomez-Arteaga, Rahul Vedula, Melhem Solh, Amandeep Salhotra, Nelli Bejanyan, Lori Muffly, Antonio Jimenez-Jimenez, Michael Drazer, Yi-Bin Chen, Aaron Logan, Reena Jayani-Kosarzycki, Sophia Balderman, James Blachly, Brian Shaffer, Marc Schwartz, Cecilia Yeung, Lawrence Druhan, Vanessa Kennedy, Sandeep Gurbuxani, Melissa Tjota, Max Smith, Farah Sahoo, Dylan Barfield, Jim Guo, James Han, Jason Hu, Heejoon Jo, Vidya Kudlingar, Wilfred Li, Yutong Qiu, Pratheesh Sathyan, Sean Truong, Severine Catreux, Sam Ng, Khai Luong, Yunjiao Zhu, Reem Bahr, Jamie Diemer, Jianqun Kou, Stephanie Bo-Subait, Jackie Bjerke, Steven Devine, Bergetta Dietel, Christina Ferrone, Gabrielle Giammarino, Emily Heying, Emily Kolb, Danielle O'Donnell Vitali, Wael Saber, Stephen Spellman, Brenna Tesch, Jenny Vogel, Stephanie Waldvogel, Syreeta Weatherspoon, Jeffery Auletta, Christopher Hourigan

Blood (2025) 146 (Supplement 1): 455.

https://doi.org/10.1182/blood-2025-455

Published: 2025

Journal Articles

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Blood (2025) 146 (Supplement 1): 5279.

https://doi.org/10.1182/blood-2025-5279

Published: 2025

Journal Articles

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Min Fang, Megan Othus, Kate Kroeger, Thaiha Nguyen, Xiaoyu QU, Brent Wood, Lyndsay Harris, Harry Erba, Jerald Radich, Richard Little, Cecilia Yeung, Shahanawaz Jiwani

Blood (2025) 146 (Supplement 1): 5276.

https://doi.org/10.1182/blood-2025-5276

Published: 2025

Journal Articles

Healthcare resource utilization and cost of molecular targeted versus non-targeted therapies in acute myeloid leukemia

Pierantonio Russo, Ramaa Nathan, Daniel Pfeffer, Alison Roos, Cecilia Yeung

Blood (2025) 146 (Supplement 1): 6207.

https://doi.org/10.1182/blood-2025-6207

Published: 2025

Journal Articles

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Blood (2021) 138 (Supplement 1): 3872.

https://doi.org/10.1182/blood-2021-149181

Published: 2021

Journal Articles

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-136440

Published: 2020

Journal Articles

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

Mazyar Shadman, MD, Ajay K. Gopal, MD, Stephen D. Smith, MD, Ryan C. Lynch, MD, Chaitra S. Ujjani, MD, Cameron J. Turtle, MBBS, PhD, Adam Greenbaum, MD PhD, Mary Redman, Cecilia Yeung, MD, Martina Sersch, MD PhD, Edus H. Warren, MD PhD, David G. Maloney, MD PhD, Brian G. Till, MD

Blood (2019) 134 (Supplement_1): 3235.

https://doi.org/10.1182/blood-2019-125102

Published: 2019

Journal Articles

New approaches to molecular monitoring in CML (and other diseases)

Jerald Radich, Cecilia Yeung, David Wu

Blood (2019) 134 (19): 1578–1584.

https://doi.org/10.1182/blood.2019000838

Published: 2019

Journal Articles

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Cameron J. Turtle, MBBS, PhD, Kevin A. Hay, MD FRCPC, MSc, Laila-Aicha Hanafi, PhD, Juliane Gust, MDPhD, W. Conrad Liles, MDPhD, José A. López, MD, Junmei Chen, PhD, Dominic W. Chung, PhD, Mark M Wurfel, MDPhD, Susanna Harju-Baker, PhD, Hasan Ozpolat, MD, Daniel Li, PhD, David Myerson, MDPhD, Luis F. Gonzalez-Cuyar, MD, Cecilia Yeung, MD, Kathleen R. Fink, MD, Stanley R. Riddell, MD, David G. Maloney, MD PhD

Blood (2017) 130 (Supplement 1): 805.

https://doi.org/10.1182/blood.V130.Suppl_1.805.805

Published: 2017

Journal Articles

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

Ryan D. Cassaday, MD, Philip A. Stevenson, MS, Bronwyn H. Bryant, MD, Cecilia Yeung, MD, Brian G. Till, MD, Stephen D. Smith, MD, Edward N. Libby, MD, Andrei R. Shustov, MD, John M. Pagel, MD PhD, Damian J. Green, MD, Mary Philip, MD PhD, Johnnie J. Orozco, MD PhD, Min Fang, MD PhD, Leona Holmberg, MD PhD, William I. Bensinger, MD, David G Maloney, MDPhD, Ajay K. Gopal, MD, Oliver W. Press, MD PhD

Blood (2014) 124 (21): 1731.

https://doi.org/10.1182/blood.V124.21.1731.1731

Published: 2014

Journal Articles

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Ekapun Karoopongse, MD, John Byon, MD, PhD, Cecilia Yeung, MD, H. Joachim Deeg, MD, A. Mario Q. Marcondes, MD, PhD

Blood (2013) 122 (21): 1543.

https://doi.org/10.1182/blood.V122.21.1543.1543

Published: 2013

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Identifying fusions in AML/MDS: An experience from first 400 patients enrolled into myelomatch

Chromosome genomic array testing (CGAT) improves diagnostic yield in patients with AML and MDS and has the potential for better risk stratefication - an NCI myelomatch and SWOG report

Impact of social determinants of health on access to molecular targeted therapy in AML and MDS: A real-world analysis

SWOG 1318: Combination of dasatinib, prednisone, and blinatumomab for older patients with Philadelphia chromosome positive acute lymphoblastic leukemia: longer follow up and predictors of outcomes

Next generation sequencing from dried blood spots: “Spot on CML” results from low- and middle-income countries

The MEASURE Genome Atlas: Acute Myeloid Leukemia at diagnosis and complete remission

Myeloid malignancies molecular analysis for therapy choice (myeloMATCH): Rapid availability of clinical, pathologic and molecular features for treatment assignment in the first 550 patients.

Biallelic TP53 aberrations and double TP53 mutations are prevalent in AML/MDS patients with del(5q) complex karyotype - an NCI myelomatch and SWOG report

Healthcare resource utilization and cost of molecular targeted versus non-targeted therapies in acute myeloid leukemia

Safety and Efficacy of Third Generation CD20 Targeted CAR-T (MB-106) for Treatment of Relapsed/Refractory B-NHL and CLL

Third Generation CD20 Targeted CAR T-Cell Therapy (MB-106) for Treatment of Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

CD20 Targeted CAR-T for High-Risk B-Cell Non-Hodgkin Lymphomas

New approaches to molecular monitoring in CML (and other diseases)

Endothelial Activation and Blood-Brain Barrier Disruption in Neurotoxicity after CD19 CAR-T Cell Immunotherapy

Failure of Intensified Induction Therapy and Inability to Undergo Stem Cell Transplantation Predict Dismal Outcomes in Relapsed/Refractory MYC + B-Cell Lymphoma

The Jumanjii Histone Demethylase KDM2B controls EZH2 Expression In Myelodysplastic Syndromes (MDS) Via Mir Let-7b (let7b), a Pathway That Is Bypassed By The Histone Methylation Inhibitor DZNep

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only